Based on these physiological mechanisms of NAFLD development, studies on applying an AT1 receptor blocker (ARB) as a therapeutic agent for NAFLD have been conducted and have shown some positive results [40]. The gene discussed is AGTR1; the disease is metabolic dysfunction-associated steatotic liver disease.